Global Denosumab Market Revenue and Share Analysis Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the denosumab market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Denosumab Market In The Period 2029-2034?

The denosumab market has experienced swift expansion in its size over recent years. Projections indicate it will expand from $3.27 billion in 2024 to $3.67 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.1%. Factors such as clinical trials and research advancements, FDA approvals and regulatory milestones, increased awareness regarding bone health, along with strategic partnerships and marketing initiatives, have fueled its historical growth.

The denosumab market size is anticipated to undergo swift expansion over the next few years. It is projected to reach $5.48 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.6%. This growth during the forecast period can be attributed to the increasing incidence of bone metastases, advancements in cancer therapies, the prevalence of osteoporosis, heightened awareness of osteoporosis, and regulatory approvals for new indications. Significant trends identified for the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, and progress in biosimilar development.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What Strategic Drivers Are Accelerating The Denosumab Market Expansion?

The rising occurrence of osteoporosis is anticipated to drive the expansion of the denosumab market. This condition, osteoporosis, involves the weakening of bones, leading to reduced bone density and an elevated risk of fractures. Denosumab addresses osteoporosis by inhibiting bone resorption through its action on the RANK ligand. As an illustration, in September 2023, the National Center for Biotechnology Information, a US government agency, reported findings from the Canadian Longitudinal Study on Aging, indicating that among community-dwelling older adult females, the prevalence of physician-diagnosed osteoporosis was 12.7%, and DXA-confirmed osteoporosis stood at 5.9%. Furthermore, a cross-sectional study by Buttros and colleagues found osteoporosis in 24.6% of postmenopausal women aged 40 to 75, identified through bone mineral density (BMD) measurements. Consequently, the growing incidence of osteoporosis is fueling the expansion of the denosumab market.

What Is The Detailed Segment Distribution Of The Denosumab Market?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

How Are Global Trends Impacting The Development Of The Denosumab Market?

Leading firms within the denosumab market are intensifying their efforts to launch pioneering solutions, like first-line osteoporosis treatments, in pursuit of a competitive advantage. A first-line treatment for osteoporosis denotes the initial or principal therapeutic strategy advised by medical experts when caring for individuals diagnosed with the condition. For example, in November 2022, Boan Biotech, a Chinese biotechnology entity, secured clearance from China’s National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, making it the inaugural Chinese company to create a denosumab injection. Its development also targets markets beyond China, encompassing Europe and the United States, with aspirations for worldwide commercialization. Numerous treatment guidelines have endorsed the drug as a first-line therapy for osteoporosis. This medication possesses the capability to significantly reduce the risk of hip, non-vertebral, and vertebral fractures in the affected patient demographic. Furthermore, Boyoubei stands as the world’s premier biosimilar to Prolia (the original denosumab product) to gain marketing approval.

Who Are The Major Stakeholders Operating In The Denosumab Market?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Denosumab Market?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

Browse Through More Reports Similar to the Global Denosumab Market 2025, By The Business Research Company

Anemia And Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Antifungals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Antiglaucoma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795